SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-21-049420
Filing Date
2021-08-03
Accepted
2021-08-03 17:39:41
Documents
1
Period of Report
2021-08-02

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 7611
  Complete submission text file 0001209191-21-049420.txt   9084
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Issuer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address
Hansen Gwenn (Reporting) CIK: 0001817160 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39398 | Film No.: 211141275